What is the fair value of Novozymes AS DRC (OTC-NVZM.Y) stock?

The current fair value estimate for Novozymes AS DRC (OTC-NVZM.Y) is $61.43. This implies an estimated downside of 4.7% versus the current market price.

Is Novozymes AS DRC (OTC-NVZM.Y) undervalued or overvalued?

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 4.7% versus the current market price.

What is the analyst price target for OTC-NVZM.Y stock?

The available analyst price target for Novozymes AS DRC (OTC-NVZM.Y) is $73. The analyst target implies estimated upside of 13.2%.

How is the financial health of Novozymes AS DRC?

The current financial health read for Novozymes AS DRC (OTC-NVZM.Y) is Good. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

When is Novozymes AS DRC's next earnings date?

The next earnings date currently listed for Novozymes AS DRC (OTC-NVZM.Y) is August 20, 2026.

Does Novozymes AS DRC (OTC-NVZM.Y) pay dividends?

Based on the current data, dividend yield is 1.3%, upcoming dividend amount is 0.59.

What is the P/E ratio for Novozymes AS DRC (OTC-NVZM.Y)?

The current P/E ratio listed for Novozymes AS DRC (OTC-NVZM.Y) is 44.2x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

What is the market capitalization of Novozymes AS DRC?

The current market capitalization listed for Novozymes AS DRC is 30.15 B.

What is the enterprise value of Novozymes AS DRC?

The current enterprise value listed for Novozymes AS DRC is 33.84 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

What is the ticker symbol for Novozymes AS DRC?

The ticker symbol for Novozymes AS DRC is OTC-NVZM.Y, and the stock is listed on OTC Markets.

Where is Novozymes AS DRC (OTC-NVZM.Y) listed?

Novozymes AS DRC (OTC-NVZM.Y) is listed on OTC Markets.

What is the debt-to-total-capital ratio for Novozymes AS DRC?

The current debt-to-total-capital ratio listed for Novozymes AS DRC is 10.8%, which helps investors evaluate the company’s financing structure and leverage profile.

What is the free float for Novozymes AS DRC?

The free float listed for Novozymes AS DRC is 74.4%. Free float helps investors understand how much of the share base is available for public trading.

Novozymes AS DRC (NVZMY) Fair Value & Stock Analysis

Novozymes AS DRC (NVZMY)

Novozymes A/S DRC is a depositary receipt listed on OTC Markets and linked to the common stock of Novozymes A/S. The underlying issuer is a Denmark-based biotechnology and industrial solutions company that develops and sells enzymes, functional proteins, and microorganisms across multiple regions, including Europe, North America, Asia Pacific, the Middle East, Africa, and Latin America. Its activities cover a broad set of end markets, including food and beverage, bioenergy, household and institutional cleaning, and human health. The company also serves agricultural, animal nutrition, textile, leather, oil and fats, plastics, and other industrial applications through a wide range of biosolution products. Novozymes A/S is headquartered in Lyngby, Denmark.

Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.

Ticker	Fair Value	Fair Value Upside/Downside	Fair Value Rating	Analyst Price Target	Analyst Target Upside/Downside	Analyst Target Rating	Overall Financial Health	Upcoming Dividend Ex-Date	Dividend Payment Date	Upcoming Dividend	Dividend Yield	Next Earnings Date	P/E Ratio	Price-to-Book Ratio	Price-to-Sales Ratio	Market Cap	Enterprise Value	Total Debt / Total Capital	Free Float / Shares Outstanding	Altman Z-Score	Payout Ratio	Free Cash Flow / Net Income
OTC-NVZM.Y	$61.43	-4.7% Downside	Fair	$73	13.2% Upside	Fair	Good	—	—	0.59	1.3%	August 20, 2026	44.2x	2.4x	6.3x	30.15 B	33.84 B	10.8%	74.4%	14.2	111.9%	140.6%